Pipelines

© GettyImages/niphon

Moderna to develop mRNA therapeutic for very rare disease

By Jane Byrne

Moderna and the nonprofit Institute for Life Changing Medicines (ILCM) are collaborating to develop a new messenger RNA (mRNA) therapeutic (mRNA-3351) for Crigler-Najjar Syndrome Type 1 (CN-1), an ultra-rare disease.

© GettyImages/Zarina Lukash

Special Edition: Reviewing the advanced therapy pipeline

Santen looks to ways to reduce hurdles for patients in accessing advanced therapies

By Jane Byrne

As a relatively new player in the field of cell therapy, Santen Pharmaceutical has outlined how it is looking to collaborate with key stakeholders in order to shape relevant policies, forge meaningful partnerships and create an optimal environment for...

Event inaugurating the new plant in Spain in June © VIVEbiotech

Special Edition: Meeting demand for viral vectors

VIVEbiotech looks to overcome challenges related to LVV production

By Jane Byrne

VIVEbiotech, a lentivirus-specialized contract development and manufacturing organization (CDMO) that produces vectors for projects from early-stage to GMP production, is working on enhancing intrinsic lentivirus characteristics and streamlining the process....

© GettyImages/koto_feja

Dispatches from Bio Digital 2021

Mogrify looks to transform cell therapy development

By Jane Byrne

Biotech, Mogrify, recently closed a Series A financing of US$17m, bringing the total raised to US$33m in the round, with the investment set to support the advancement of the company’s immuno-oncology and ophthalmology programs.

© GettyImages/Design Cells

4D Pharma expanding clinical data in multiple indications

By Jane Byrne

Live biotherapeutic product (LBP) developer, 4D Pharma, says it is building a ‘strong body of evidence’ for its portfolio of bacterial strains in relation to cancer, asthma, and neurodegenerative diseases, while the company also calls its recent dual...

© GettyImages/Urupong

Dispatches from Bio Digital 2021

Pfizer CEO: ‘There is renewed hope and trust in science’

By Jane Byrne

A lesson learnt from the COVID-19 pandemic was that human ingenuity prevailed and resolved an issue that challenged the world; the crisis also reinforced faith in the power of science, said Dr Albert Bourla, CEO of Pfizer, in a keynote interview during...